Pharsight

Drugs that contain Metformin Hydrochloride; Sitagliptin Phosphate

1. Janumet patents expiration

JANUMET's oppositions filed in EPO
JANUMET Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 6 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 6 months ago)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 29 days ago)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 29 days ago)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(3 years from now)

US8414921 MERCK SHARP DOHME Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jul, 2028

(4 years from now)

US8414921

(Pediatric)

MERCK SHARP DOHME Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jan, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Jun 4, 2024

Market Authorisation Date: 30 March, 2007

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin; Method of treating type 2 diabetes mellitus by administering a dipeptidyl p...

Dosage: TABLET;ORAL

How can I launch a generic of JANUMET before it's drug patent expiration?
More Information on Dosage

JANUMET family patents

Family Patents

2. Janumet Xr patents expiration

JANUMET XR's oppositions filed in EPO
JANUMET XR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 6 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 6 months ago)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 29 days ago)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 29 days ago)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Jun 4, 2024

Market Authorisation Date: 02 February, 2012

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JANUMET XR before it's drug patent expiration?
More Information on Dosage

JANUMET XR family patents

Family Patents